Market Size of MEA Uterine Cancer Therapeutics & Diagnostics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 5.70 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
MEA Uterine Cancer Therapeutics & Diagnostics Market Analysis
The Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market is expected to grow with a CAGR of 5.7% during the forecasted period. The key factors propelling the growth of this market are rise in awareness about uterine diseases and their available therapies, increasing health care expenditure in drug development, and subsequent technological advancements.
In South Africa, the Cancer Association of South Africa (CANSA) is an organization that offers integrated services to the people affected by cancer in the country. Its mission involves providing research with regards to lowering cancer risk, educating the public regarding symptoms, screening and risk reduction, and providing care and support to all those affected by cancer. Furthermore, the department of Health in South Africa implemented programs to improve the health of women, all these programs is expected to increase early diagnosis procedures in near future.
As per National Clinical Trials (NCT) Registry, as of June 18, 2020, in Saudi Arabia "ASPIRE" clinical trial which is under phase II development for the treatment of endometrial cancer with stereotactic ablative radiation (SABR/SBRT) therapy. In near future, if trial shows positive outcome then it will boost the market as new therapy can be expected in coming years.
Therefore, these initiatives and research efforts are expected to boost the market in the region, in future.
